comparemela.com

Latest Breaking News On - Gitte moos knudsen - Page 1 : comparemela.com

Cybin s Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What s Next? - Cybin (AMEX:CYBN)

Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing st

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose - - Primary efficacy endpoint.

Psychiatric Patients with Poor Verbal Memory More Likely to be Hospitalized

Psychiatric Patients with Poor Verbal Memory More Likely to be Hospitalized
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.